Vor Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio granted 4,373,040 stock options and 937,080 RSUs to its newly appointed Chief Development Officer, Dr. Qing Zuraw. The stock options have a ten-year term and an exercise price of $2.38 per share, while the RSUs will vest over four years. The grants were made under the Vor Biopharma Inc. 2023 Inducement Plan and are contingent on Dr. Zuraw's continued employment with Vor Bio.

Cambridge, Mass., July 2, 2025 — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, has announced a substantial equity incentive package for its newly appointed Chief Development Officer, Dr. Qing Zuraw. The package includes 4,373,040 stock options and 937,080 restricted stock units (RSUs) [1].

The stock options, with a ten-year term and an exercise price of $2.38 per share, were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and the Vor Biopharma Inc. 2023 Inducement Plan [2]. They will vest over a four-year period, with 25% vesting one year from the grant date and the remaining 75% vesting in equal monthly installments over the following three years [3].

Similarly, the RSUs will vest over a four-year period, with 25% vesting on August 1, 2026, and the remaining 75% vesting in equal quarterly installments over the subsequent three years, subject to Dr. Zuraw's continued employment with Vor Bio [4].

Dr. Zuraw's appointment underscores Vor Bio's commitment to attracting top talent in the biotechnology field and aligning executive compensation with long-term performance and retention [5]. The company is focused on advancing its lead program, telitacicept, through Phase 3 clinical development, addressing a significant market need in the treatment of autoimmune diseases [6].

References:
[1] https://ir.vorbio.com/news-releases/news-release-details/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-9
[2] https://www.gurufocus.com/news/2988440/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-vor-stock-news
[3] https://www.stocktitan.net/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-5r2qra9owqfq.html
[4] https://www.nasdaq.com/articles/vor-bio-grants-stock-options-and-rsus-new-chief-development-officer-dr-qing-zuraw
[5] https://www.gurufocus.com/news/2988440/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-vor-stock-news
[6] https://ir.vorbio.com/news-releases/news-release-details/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-9